- Short report
- Open Access
Circumventing qPCR inhibition to amplify miRNAs in plasma
Biomarker Researchvolume 2, Article number: 13 (2014)
Circulating microRNAs (c-miRNAs) have be identified in saliva, urine and blood, which has led to increasing interest in their development as biomarkers for diverse diseases including cancers. One of the key advantages of c-miRNAs over other biomarkers is the ability to be amplified and quantified by quantitative PCR (qPCR). However, at phlebotomy when whole blood is dispensed into heparinized tubes, residual levels of the anti-coagulant lithium heparin may remain in the plasma and hence with RNA isolated from the plasma. This can confound the detection of c-miRNAs by qPCR because it inhibits reverse transcriptase (RT). Here we present a procedure, modified from earlier techniques, to detect c-miRNAs in plasma that improves sensitivity and streamlines performance.
Treatment of total RNA isolated from human blood plasma with Bacteroides heparinase I during reverse transcription at 37°C for one hour improved sensitivity and performance of the qPCR. This is in comparison to no treatment or treatment of the RNA prior to RT, which is the current suggested method and exposes plasma to Flavobacterium heparinum heparinase I for up to 2 hours before RT. This modest alteration improved qPCR performance and resulted in lowered threshold cycles (Ct) for detection of the target sequence, candidate c-miRNA biomarkers, and controls. It also reduced the expense and number of processing steps, shortening the duration of the assay and minimizing exposure of RNA to elevated temperatures.
Incorporating Bacteroides heparinase I treatment into conventional RT protocols targeting c-miRNA in plasma can be expected to expedite the discovery of biomarkers.
Non-coding RNAs, including microRNAs (miRNAs), are increasingly the target of biomarker development . These molecules play a central role in gene expression regulation, in particular at the posttranscriptional and homeostatic levels [2, 3], and have been detected in specimen matrices used for cancer biomarker development, including solid tissues, urine, sera, and blood. [4–6]. Indeed, miRNAs have been developed as informative markers for breast , colorectal  and ovarian cancers [8, 9]. As biomarkers, circulating miRNAs (c-miRNAs) may be preferable to miRNAs located in solid tumor tissues due to their accessibility, stability during storage, and the increased specificity and sensitivity of multiplexed assays i.e., approaches that allow the analysis of panels of c-miRNAs assembled together to identify miRNA signatures. Discovery of c-miRNAs biomarkers frequently begins with high throughput approaches such as microarrays or small RNA-Seq with subsequent verification by quantitative reverse transcription PCR (qPCR). The qPCR represents a confirmatory step that allows either absolute or relative quantitation of miRNAs expression, by integrating a standard curve or a reference control gene in the analysis, respectively .
In this short report we present a modified method for qPCR detection of c-miRNAs in plasma from human blood, collected using an anticoagulant, such as lithium heparin. Whereas most macromolecular constituents of plasma and serum are the same, and both are devoid of platelets, red and white blood cells, sera and plasma can be used interchangeably in serological analysis targeting antibodies or antigens . However, plasma - unlike serum - retains the coagulation cascade clotting factors and fibrinogen, and problematically, exogenous anticoagulant(s) that block the blood from clotting. This presence of extraneous anticoagulants can interfere with the qPCR, including reverse transcription of the RNA to cDNA and amplification of the target cDNA [12–14]. Here we present an alternative to conventional approaches to overcome the inhibition from residual heparin in qPCR to detect c-miRNAs in plasma. These modifications to previously reported methods not only improved the qPCR but also reduced costs and streamlined the analysis by shortening processing time, and, thereby reduced the likelihood of RNA degradation.
Duplicate RT reactions were performed along with duplicate qPCRs for all the samples. The findings were compared with informative reports from others dealing with detection of c-miRNAs in sera. In ongoing studies, we plan to employ this modified protocol in discovery and validation of c-miRNAs as biomarkers for liver fluke induced cholangiocarcinoma (CCA) , with plasma collected in a longitudinal study and biobanked at -80°C. RNA was recovered from plasma (250 μl) using the QIAamp circulating nucleic acids kit (Qiagen) following the manufacturer’s standard protocol. In most cases, the RNA was reverse transcribed using the miScript II RT Kit (Qiagen) in HiSpec buffer and cDNA screened on custom miScript miRNA PCR Arrays (SA Biosciences). qPCR was performed with SYBR Green PCR Master Mix (miScript, Qiagen), a thermocycler (iCycler, Bio-Rad, Hercules, CA) fitted with real time detector (Bio-Rad iQ5), and the following thermal cycling: activation at 95°C, 15 min; 40 cycles of denaturation, 15 sec, 94°C, annealing, 30 sec 55°C, extension, 30 sec, 70°C); melting curve analysis, 81 cycles of 55°C, 20 sec dwell.
In contrast to studies using sera, miRNAs were not detectable from plasma (Figure 1A and B), including miRTC controls (miRTC: Reverse transcriptase qPCR; Qiagen) at 45 thermal cycles while PPC (Positive qPCR Controls, Qiagen) Ct values ranged from 18 and 20. To address this problem, we extracted RNA using the miRNeasy serum/blood plasma kit (Qiagen), which uses phenol and chloroform, and as a positive control, spiked plasma with C. elegans miR-39 mimic (Qiagen) . The yield of RNA derived from plasma in both the QIAamp and miRNAeasy methods was 8-12 ng/μl, and was of similar quality to that we have recovered from sera , although RNA from plasma exhibited lower 260/230 ratios, (<0.7) with the miRNeasy kit. However, when RNA isolated using miRNeasy was subjected to qPCR, the Ct values did not improve, including for control C. elegans miR-39 which was employed to spike plasma (Figure 1A and B). This suggested interference, likely during reverse transcription; notably, the matrix of the original stored specimens - plasma versus serum - represented the only apparent difference from the previous analysis . In reviewing the literature [12, 13, 18, 19], a modified protocol was outlined for testing to overcome the residual heparin interference.
The first modification included in the approach for processing plasma (Experiment 1, Figure 1A and B) was replacement of Flavobacterium heparinum heparinase I with Bacteroides heparinase I (New England BioLabs) during RT (Experiment 1, Figure 1A and B). Bacteroides heparinase I cleaves 2-O-sulfated glucuronic acid residues in heparin in addition to the glycosidic bond between N-sulfated hexosamines and 2-O-sulfated iduronic acid residues cleaved by heparinase of F. heparinum [18, 19]. Three reaction conditions were compared: (1) pre-treatment of RNA with B. heparinase I; (2) co-treatment of RNA during RT with B. heparinase I; and (3) pre-amplification. For pre-treatment of the RNA before RT [12, 13], 0.6 U and 6.0 U Bacteroides heparinase I were incubated with 3 μl RNA for 2 h at 25°C then subsequently reverse transcribed. For co-treatment, the miScript II RT reaction (reaction volume, 20 μl) included 6 U Bacteroides heparinase I, 4 μl HiSpec 5× buffer, 2 μl 10× nucleic acids, 2 μl reverse transcriptase mix, and 3 μl RNA. For pre-amplification, the RT reaction was carried out according to the manufacturer’s protocol with the miScript Pre-AMP PCR Kit (Qiagen) for 12 cycles. In all cases, reverse transcription was carried out at 37°C for 1 h after which the RT was inactivated at 95°C, 5 min. The reaction products were diluted to 200 μl with water, stored on wet ice or at -80°C and analyzed by qPCR on miScript miRNA QA PCR Arrays (SA Biosciences). Minimal or no improvement was seen with the pre-amplification kit for the miRTC controls. By contrast, incubation with Bacteroides heparinase I before and during RT resulted in detectable miRTC values, with optimal amplification observed after inclusion of 6 U Bacteroides heparinase I during RT: miRTC, Ct ~28 (Figure 1B and C), PPC (Figure 1B and D), and miR-39, Ct ~26.5 (Figure 1B and E).
Because it eliminated one reaction step and thereby reduced exposure time of the RNA to elevated temperatures, co-treatment or inclusion of Bacteroides heparinase I during RT was examined, aiming for further improvement. Four conditions were tested: 0.6 U, 6 U and 12 U of Bacteroides heparinase I, with increasing quantities of RNA from 3 to 6 μl (Experiment 2; Figure 1A and B). Here Ct values were inversely related to the concentration of Bacteroides heparinase I (Figure 1B). Moreover, using 12 U Bacteroides heparinase I with 3 μl and 6 μl RNA resulted in miRTC values that were ≤ 5 cycles less than the positive qPCR controls (PPC) (Figure 1B, F, G and H). Last, to determine potentially negative influences of the RNA purification (QIAamp versus miRNeasy) on residual lithium heparin, RNA from QIAamp purifications (3 μl, 6 μl RNA) was also tested. In this case, QIAamp purifications were likely to have included more residual heparin since the plasma was not subjected to extraction in phenol-chloroform, and was in turn exposed to 12 U of Bacteroides heparinase I during RT. This condition yielded similar signals to matched samples treated as above (Figure 1B). To summarize, treatment with 12 U of Bacteroides heparinase I during RT at 37°C with 3 μl or 6 μl RNA delivered strong, positive and reproducible qPCR signals, markedly improving outcomes over no treatment or strategies similar to methods reported previously [12, 13]. Additionally, co-treatment with Bacteroides heparinase I during RT offers the following advantages: 1) streamlines the protocol, without additional steps and reducing process times compared to earlier methods; 2) limits exposure of RNA to deleterious conditions including elevated temperatures for prolonged periods; and 3) improves sensitivity of qPCR compared to no-treatment or other approaches (Figure 2).
To confirm that this modified method for Bacteroides heparinase I improved sensitivity not only with assay and reaction controls, i.e., PPC, miRTC, miR-39, but could also be extrapolated to biomarker discovery, we examined the Ct results from a custom miScript miRNA PCR Array (SA Biosciences) across 19 discrete plasma samples. The arrays included 94 miRNA (mature, human) primers that provide potential signatures for cholangiocarcinoma . We used 12 U Bacteroides heparinase I during RT and compared this with no-treatment of RNA. Without treatment, miRNAs remained undetected below 45 cycles on the custom miRNA array. By contrast, inclusion of Bacteroides heparinase I during RT significantly improved the sensitivity of detection: ~50% of the target miRNAs were detected at ≤ 35 cycles (Figure 3). Using this method, RNA from plasma was reproducibility reverse transcribed and amplified despite the presence of residual heparin in the plasma. Further, the miRTC and the ce-miR-39 spiked controls for 19 plasma samples from our investigation of biomarkers for CCA  are presented in Additional file 1: Figure S1. To conclude, the method presented here may be applicable to the analysis of miRNAs derived from blood, and should be especially advantageous for plasma from heparinized blood and/or where sera are unavailable.
Institutional Review Board of the George Washington University determined that the plasma samples used in this study did not meet the definition of human subjects research; i.e., a living individual about whom an investigator conducting research obtains: a) data through intervention or interaction with the individual or b) private identifiable information. This determination was made since the samples were limited to pre-existing, de-identified specimens labeled with a random code.
circulating miRNA (microRNA, micro-RNA)
Reverse transcriptase qPCR controls (Qiagen)
Positive qPCR Controls (Qiagen)
quantitative PCR (real-time PCR)
Reverse transcriptase and/or reverse transcription.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6: 857–866. 10.1038/nrc1997
Sun W, Li YSJ, Huang HD, Shyy JYJ, Chien S: microRNA: A master regulator of cellular processes for bioengineering systems. Ann Rev Biomed Eng 2010, 12: 1–27. 10.1146/annurev-bioeng-070909-105314
He L, Hannon GL: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5: 522–531. 10.1038/nrg1379
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281–297. 10.1016/S0092-8674(04)00045-5
Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, Bertone B, Caldas C: Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010, 16: 991–1006. 10.1261/rna.1947110
Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010, 5: e13515. 10.1371/journal.pone.0013515
Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010, 25: 1674–1680. 10.1111/j.1440-1746.2010.06417.x
Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112: 55–59. 10.1016/j.ygyno.2008.08.036
Mostert B, Sieuwerts AM, Martens JW, Sleijfer S: Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Exp Rev Mol Diagn 2011, 11: 259–275.
Ginzinger DG: Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 2002, 30: 503–512. 10.1016/S0301-472X(02)00806-8
Siev M, Yu X, Prados_Rosales R, Martiniuk FT, Achkar JM: Correlation between serum and plasma antibody titers to mycobacterial antigens. Clin Vaccine Immunol 2011, 18: 173–175. 10.1128/CVI.00325-10
Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA: Heparinase treatment of RNA before quantitative real-time RT-PCR. Bio Tech 2003, 35: 1140–1142. 1144
Bai X, Fischer S, Keshavjee S, Liu M: Heparin interference with reverse transcriptase polymerase chain reaction of RNA extracted from lungs after ischemia-reperfusion. Transpl Int 2000, 13: 146–150. 10.1111/j.1432-2277.2000.tb01055.x
Garcia ME, Blanco JL, Caballero J, Gargallo-Viola D: Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol 2002, 40: 1567–1568. 10.1128/JCM.40.4.1567-1568.2002
Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM, Loukas A: The tumorigenic liver fluke Opisthorchis viverrini -- multiple pathways to cancer. Trends Parasitol 2012, 28: 395–407. 10.1016/j.pt.2012.07.006
Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP: The microRNAs of Caenorhabditis elegans . Gen Dev 2003, 17: 991–1008. 10.1101/gad.1074403
Plieskatt JL, Rinaldi G, Feng Y, Levine PH, Easley S, Martinez E, Hashmi S, Sadeghi N, Brindley PJ, Bethony JM, Mulvenna JP: Methods and matrices: approaches to identifying miRNAs for Nasopharyngeal carcinoma. J Trans Med 2014, 12: 3. 10.1186/1479-5876-12-3
Merchant ZM, Kim YS, Rice KG, Linhardt RJ: Structure of heparin-derived tetrasaccharides. Biochem J 1985, 229: 369–377.
Yamada S, Murakami T, Tsuda H, Yoshida K, Sugahara K: Isolation of the porcine heparin tetrasaccharides with glucuronate 2-O-sulfate. Heparinase cleaves glucuronate 2-O-sulfate-containing disaccharides in highly sulfated blocks in heparin. J Biol Chem 1995, 270: 8696–8705.
Plieskatt JL, Rinaldi G, Feng Y, Peng J, Yonglitthipagon P, Easley S, Laha T, Pairojkul C, Bhudhisawasdi V, Sripa B, Brindley PJ, Mulvenna JP, Bethony JM: Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumorigenic liver fluke Opisthorchis viverrini. J Hepatol 2014. doi:10.1016/j.jhep.2014.05.035
This research was partially supported by awards R01CA155297 (JMB, PJB) from the National Cancer Institute, National Institutes of Health, P50 AI098639 (JMB, PJB) from the National Institute of Allergy and Infectious Diseases, the Dr. Cyrus and Myrtle Katzen Cancer Research Center at the George Washington University (PJB, JMB), and award GNT1051627 from the National Health and Medical Research Council of Australia (JPM, JMB). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID, NCI, or NIH.
The authors declare no competing interests.
JLP and YF carried out the assays; JLP optimized reaction conditions. JMB, GR, JPM, and PJB provided technical oversight and assisted in the preparation of the manuscript with JLP. All authors read and approved the final manuscript.